Biocept (NASDAQ:BIOC) Releases Quarterly Earnings Results, Misses Expectations By $0.19 EPS

Share on StockTwits

Biocept (NASDAQ:BIOC) issued its quarterly earnings data on Monday. The medical research company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.19), Morningstar.com reports. The company had revenue of $1.19 million for the quarter. Biocept had a negative return on equity of 338.61% and a negative net margin of 695.85%.

Shares of NASDAQ:BIOC opened at $1.04 on Wednesday. The stock has a market cap of $19.25 million, a P/E ratio of -0.12 and a beta of 1.93. The company has a quick ratio of 2.63, a current ratio of 2.72 and a debt-to-equity ratio of 0.10. Biocept has a twelve month low of $0.66 and a twelve month high of $4.02. The business’s 50 day moving average is $1.04.

Several analysts have recently weighed in on BIOC shares. Maxim Group restated a “buy” rating and set a $3.00 price objective on shares of Biocept in a research report on Thursday, May 9th. ValuEngine upgraded shares of Biocept from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.

An institutional investor recently raised its position in Biocept stock. Dimensional Fund Advisors LP increased its holdings in Biocept Inc (NASDAQ:BIOC) by 180.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 110,500 shares of the medical research company’s stock after acquiring an additional 71,055 shares during the quarter. Dimensional Fund Advisors LP owned approximately 4.86% of Biocept worth $95,000 at the end of the most recent quarter. Institutional investors own 2.34% of the company’s stock.

Biocept Company Profile

Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.

Featured Article: How to interpret Moving Average Convergence Divergence (MACD)

Earnings History for Biocept (NASDAQ:BIOC)

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Sigma Planning Corp Invests $214,000 in SPDR Portfolio S&P 500 Growth ETF
Sigma Planning Corp Invests $214,000 in SPDR Portfolio S&P 500 Growth ETF
IPG Photonics Co.  Shares Sold by Swiss National Bank
IPG Photonics Co. Shares Sold by Swiss National Bank
Brokerages Set Avid Technology, Inc.  Target Price at $9.17
Brokerages Set Avid Technology, Inc. Target Price at $9.17
Intercontinental Wealth Advisors LLC Has $524,000 Stock Holdings in Exxon Mobil Co.
Intercontinental Wealth Advisors LLC Has $524,000 Stock Holdings in Exxon Mobil Co.
Brokerages Set BRT Apartments Corp  Price Target at $13.50
Brokerages Set BRT Apartments Corp Price Target at $13.50
Amazon.com, Inc.  is Truehand Inc’s Largest Position
Amazon.com, Inc. is Truehand Inc’s Largest Position


© 2006-2019 Ticker Report